期刊文献+

抗人晚期糖基化终产物受体胞外段不同表位单克隆抗体的制备 被引量:6

Preparation of monoclonal antibodies against different epitopes on extracellular domain of human receptor for advanced glycation end product
下载PDF
导出
摘要 目的 制备抗人晚期糖基化终产物受体(RAGE)胞外段单克隆抗体。方法 用纯化人重组RAGE胞外段(氨基酸序列23~342)免疫Balb/c小鼠,取其脾细胞与NS—1融合制备杂交瘤,经筛选和两次克隆化,从制备的腹水中纯化单克隆抗体。结果和结论 获得两株杂交瘤细胞B2.2和E10,其分泌单抗的亚型均为IgG2b。经ELISA、Westernblot和流式细胞仪鉴定,证明两株单抗均可结合重组RAGE及表达于细胞表面的RAGE,且两株抗体识别的位点为远隔表位,所建立的双夹心法可用于检测可溶性重组RAGE。这两株抗体将为研究RAGE相关疾病提供有效的工具。 Objective To prepare and characterize monoclonal antibodies (mAb) against recombinant human receptor for advanced glycation end product (rhRAGE). Methods BALB/c mice were immunized with recombinant extracellular domain(amino acid 23-342) of human advanced glycation end product (RAGE), and hybridoma was generated with mouse spleen cells and myeloma NS-1 cells. After three fusions and cloning, two hybridoma cell lines secreting monoclonal antibodies to RAGE were obtained and monoclonal antibodies were purified from the ascites followed by characterization with indirect enzyme-linked immunosorbent assay (ELISA), flow cytometry and Western blotting. Results and Conclusion Two hybridoma cell lines secreting anti-RAGE mAb were established and designated as B2.2 and E10, respectively. Both of mAb B2.2 and E10 belonged to IgG2b isotype and could bind to recombinant RAGE and natural RAGE expressed on THP-1 cells. In addition, B2.2 and E10 could recognize different epitopes of RAGE, which were conformed to be capable of detecting soluble recombinant RAGE in sandwich ELISA. These two mAbs against different epitopes of rhRAGE would be useful for study of glycation end product and RAGE-related diseases.
出处 《第一军医大学学报》 CSCD 北大核心 2004年第2期129-132,共4页 Journal of First Military Medical University
基金 国家自然科学基金重点项目(30330300) 广东省团队项目(010717)~~
关键词 抗人晚期糖基化终产物受体 单克隆抗体 制备 RAGE胞外段 远隔表位 流式细胞仪 鉴定 extracellular domain, RAGE monoclonal antibody separate epitope
  • 相关文献

参考文献9

  • 1[1]Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues[J]. Am J Pathol, 1993, 143(6): 1699-712.
  • 2[2]Hori O, Yan SD, Ogawa S, et al. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus [J]. Nephrol Dial Transplant, 1996,11 (Suppl 5):13-6.
  • 3[3]Miyata T, Hori O, Zhang J, e t al Thereceptor for advaneed glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononucleεr phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis [J ]. J Clin Invest, 1996, 98(5): 1088-94.
  • 4[4]Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer'sdisease [J]. Brain Res, 2001, 888 (2):256-62.
  • 5[5]Chappey O, Dosquet C, Wautier MP, et al. Advanced glycation end products, oxidant stress and vascular lesions[ J ]. Eur J Clin Invest,1997, 27(2): 97-108.
  • 6[6]Hsieh HL, Schafer BW, Sasaki N, et al. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays [ J ].Biochem Biophys Res Commun, 2003, 307(2): 375-81.
  • 7[7]Ishihara K, Tsutsumi K, Kawane S, et al. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site[J]. FEBS Lett, 2003, 550(1-3): 107-13.
  • 8[8]Hou FF, Chertow GM, Kay J, et al. Interaction between β 2m and AGE in the development of dialysis-related amyloidnsis[J]. Kidney Int, 1997, 51(5): 1514-9.
  • 9[9]Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy, soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rat[J]. J Clin Invest, 1996, 97(1): 238-43.

同被引文献65

  • 1朱荫昌.日本血吸虫病免疫发病机理研究的进展[J].中国血吸虫病防治杂志,1994,6(S1):32-40. 被引量:3
  • 2[10]Hou FF, Jiang JP, Guo JQ et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol,2002,13(5):1296
  • 3[11]Schmidt A M, Mora R, Cao R et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and lactoferrin-like polypeptide. J Biol Chem,1994,269(13):9882
  • 4[12]Owen WF Jr, Hou FF, Stuart RO et al. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int, 1998, 53(5):1365
  • 5[13]Mercie P, Seigneur M, Bilhou-Nabera C et al. Nuclear transcription factor kappa B(NF- kappa B). Rev Med Interne ,1998,19:945
  • 6[14]Griending KK, Sorescu D et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol, 2000,20(10):2175
  • 7[1]Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kindney Dis,1995,26(6):875
  • 8[2]Hou FF, Owen WF Jr. Beta 2-microglobulin amyloidosis: role of monocytes/macrophages. Curr Opin Nephrol Hypertens,2002, 11(4):417
  • 9[3]Miyata T, Sugiyama S, Saito A et al. Reaction carbony1 compounds related uremic toxicity "carbony1 stress". Kidney Int, 2001, 78:S25
  • 10[5]Hou FF ,Boyce J, Chertow GM et al. A minoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol,1998,9(2):277

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部